Chr t(14;16)

P1/2, N=70, Recruiting, Wake Forest University Health Sciences | Active, not recruiting --> Recruiting

Nevertheless, when co-segregation was eliminated, the detrimental effect of +1q or del(1p) was no longer observed. In conclusion, this study confirms the prognostic significance of high-risk cytogenetic abnormalities in MM and highlights the importance of considering co-occurrence for accurate prognosis assessment.

P2; Recruiting --> Active, not recruiting | Trial completion date: Mar 2029 --> Dec 2030 | Trial primary completion date: Mar 2026 --> Dec 2026

P1, N=20, Completed, Noah Merin | Active, not recruiting --> Completed | N=30 --> 20 | Trial completion date: Nov 2031 --> Nov 2024

P1/2, N=70, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Oct 2024 --> Nov 2032 | Trial primary completion date: Oct 2024 --> Apr 2029

P2, N=52, Active, not recruiting, Academic and Community Cancer Research United | Recruiting --> Active, not recruiting

Early recognition and prompt intervention are essential in managing MM patients, especially in those with high-risk cytogenetic abnormalities. This case serves as a reminder for clinicians to maintain a high index of suspicion for MM, even in younger populations, when presented with unexplained kidney injury.

P2, N=29, Active, not recruiting, Emory University | Trial completion date: Aug 2024 --> Mar 2026 | Trial primary completion date: Jul 2024 --> Mar 2025

P1/2, N=20, Active, not recruiting, Ciusss de L'Est de l'Île de Montréal | Trial primary completion date: Sep 2021 --> Oct 2023

P3, N=1087, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Nov 2023 --> Nov 2025

CD34+ stem cells (SC) mobilization was performed with cyclophosphamide (2-4 g/smq) and G-CSF in 26 patients (74%) after a median time of 28 days (range: 13-50 221 Posters days) from the end of induction; 3 (11%) patients were mobilized only with G-CSF. Plerixafor on demand was administered in 13 pts (50%) failing to achieve the desired collection target...Hematological toxicity was the most common adverse event (50%; G≥3 anemia, neutropenia, thrombocytopenia occurred in 8%, 17% and 8% respectively), followed by infections (33%) and PNP (25%). In our real-life experience, D-VTD regimen was proven effective and well tolerated in TE-NDMM patients.

A novel NGS targeted panel was designed and successfully validated, whose main novelty resides in the possibility to call CNAs from off-target reads, that can be used to define MM pts’ genomic risk factors, possibly required in the daily clinical practice. Thanks to AIRC IG2018-22059, AILBolognaODV.